PubMed Health⌕ Search

Biomedical subjects

K S Zuckerman

Publications and source records attributed to K S Zuckerman.

At least 55 records · Page 3Linked to original sources

Inhibition of collagen deposition in the extracellular matrix prevents the establishment of a stroma supportive of hematopoiesis in long-term murine bone marrow cultures.

Long-term production of murine hematopoietic cells in vitro is dependent on establishment of a complex microenvironment consisting of a variety of stromal cells and an extensive extracellular matrix which includes collagen, fibronectin, laminin, proteoglycans, and other undefined components adherent to the culture dishes. Cis-4-hydroxyproline (CHP), a relatively specific inhibitor of collagen secretion, was used to examine the role of extracellular collagen deposition in supporting hematopoiesis in long-term C57B1/6J mouse bone marrow cell cultures. Throughout the 10-wk culture period, all culture dishes contained either 0, 10, 25, or 50 micrograms/ml of CHP. All medium and nonadherent cells were removed at weekly intervals and replaced with fresh medium containing the previous concentrations of CHP. Nonadherent cells were assayed weekly for total cells and pluripotent, erythroid, megakaryocytic, and granulocytic-macrophage progenitor cells. Dishes were killed at selected intervals to assess protein and collagen synthesis in the adherent layer. Adherent cell numbers, as judged by microscopic examination and DNA assays, correlated inversely with CHP concentrations used and paralleled degree of collagen synthesis inhibition. The decreased hemopoietic progenitor cell production correlated closely with percent inhibition of collagen synthesis and stromal cellularity. The CHP concentrations tested were not directly toxic to hemopoietic progenitor cells. These studies demonstrate that collagen deposition in the extracellular matrix of murine bone marrow cell cultures is essential to the establishment of a functional stromal microenvironment that is supportive of long-term hematopoiesis.

Animals↗

Serotonin uptake by progeny of murine megakaryocyte precursors (CFU-M) in vitro.

Normal megakaryocytes take up and store serotonin (5-hydroxytryptamine) (5-HT). Murine megakaryocyte colonies were grown in plasma clot cultures, labeled autoradiographically with 3H-5-HT-creatinine sulfate, and stained for acetylcholinesterase. Silver granules representing serotonin uptake were present over almost all acetylcholinesterase-positive cells, including both mature megakaryocytes and smaller mononuclear cells. There was no evidence of serotonin accumulation in non-acetylcholinesterase staining granulocytic, monocytic, or erythroid cells. The results of this study provide: (a) a new label to identify murine megakaryocytes and smaller mononuclear megakaryocyte precursors (progeny of CFU-M) in plasma clot cultures, (b) further evidence that immature acetylcholinesterase-positive megakaryocyte precursor cells possess the ability to take up and store serotonin, and (c) evidence that this function of megakaryocytes and megakaryocyte precursors is preserved in the artificial environment of plasma clot cultures.

Acetylcholinesterase↗

Colchicine therapy for refractory idiopathic thrombocytopenic purpura.

Fourteen patients with idiopathic thrombocytopenic purpura (ITP) refractory to splenectomy and corticosteroids (prednisone, 1 to 2 mg/kg of body weight per day) received at least 1.2 mg of oral colchicine daily for a minimum of two weeks. Three patients had complete responses and one had a partial response (response rate, 29%). Responses were evident within two weeks of commencing therapy. Only the patient with a partial response was receiving concomitant therapy, a stable dose of prednisone. Responsiveness to colchicine did not seem to correlate with responsiveness to vincristine sulfate. Side effects of colchicine therapy were mild and complications did not occur. A possible mechanism of action for colchicine in ITP is decreased clearance of opsonized platelets secondary to inhibition of microtubule-dependent events in macrophages. Colchicine is useful in the treatment of ITP resistant to standard treatment.

Administration, Oral↗

Mitogen-induced stimulation and suppression of erythroid burst promoting activity production by human mononuclear cells.

Exposure of human peripheral blood mononuclear cells or highly enriched monocytes to various plant lectins substantially alters their production of erythroid burst promoting activity (BPA). Neither unstimulated, nor mitogen stimulated, enriched T lymphocytes produced demonstrable BPA. Each of the lectins tested resulted in a different pattern of alteration of BPA production by mononuclear cells. Increasing concentrations of phytohaemagglutinin (PHA) caused a progressive increase in BPA production up to a plateau level at concentrations above 0.25-0.5 microliter/ml. Concanavalin A (Con A) at concentrations of 0.05-0.1 micrograms/ml stimulated BPA production, but Con A concentrations greater than 1 microgram/ml never augmented BPA production by mononuclear cells. Pokeweed mitogen inhibited BPA production by mononuclear cells in a concentration-dependent manner. Since PHA and Con A can bind to and stimulate both monocytes/macrophages and T lymphocytes, some production of BPA by stimulated T cells in the presence of monocytes cannot be ruled out. Earlier studies demonstrated that T cells augment monocyte production of BPA. Thus, monocyte-T cell interactions, as well as activation of monocytes and perhaps lymphocytes, play an important role in regulation of BPA production in vitro.

Adult↗

Extracellular matrix production by the adherent cells of long-term murine bone marrow cultures.

We have studied the deposition of extracellular matrix proteins in the adherent stroma of long-term murine bone marrow cultures. Stable hematopoiesis was maintained for greater than 12 wk. At selected intervals, culture dishes were sacrificed by removing all nonadherent cells and air drying the dishes. The adherent stromal layer was analyzed for the presence of intracellular and extracellular collagen, fibronectin, and laminin using double immunofluorescent staining with specific antisera against these matrix components. In cultures examined during the first 2 wk, large numbers of stromal cells contained collagen, fibronectin, and laminin. Over the next 2 wk, an extensive extracellular network of fibronectin, laminin, and collagen was deposited on the dishes, which persisted throughout the life of the cultures. In contrast to a previous report, we detected substantial numbers of endothelial cells by means of immunofluorescent staining of stromal cells with antisera to type IV collagen, laminin, and factor VIII antigen. Although deposition of these extracellular matrix proteins coincides with onset of active hematopoietic cell production, the relative roles of the stromal cells and the extracellular matrix in supporting hematopoiesis in murine bone marrow cell cultures remain to be determined.

Animals↗

Production of human erythroid burst promoting activity by monocytes stimulated with bacterial lipopolysaccharide.

We examined production of erythroid burst promoting activity (BPA) in media conditioned by unstimulated or bacterial lipopolysaccharide (LPS) stimulated human blood mononuclear cells (MNC) and highly purified (greater than or equal to 96%) monocytes and T lymphocytes. Human erythroid progenitor (BFUE) growth from monocyte depleted MNC was reduced to 8.6% of control growth in cultures of unfractionated MNC. BPA was assayed by determining the ability of 10% conditioned medium to augment BFUE growth from monocyte depleted MNC to greater than the baseline of 8.6% of control. BPA production by unstimulated monocytes was greatest with 1-5 X 10(5) monocytes/ml. Monocytes stimulated by LPS 0.1-100 micrograms/ml produced 50 to 150% more BPA than did unstimulated monocytes. T lymphocytes (10(5) per ml) produced no detectable BPA. LPS alone caused no change or actually inhibited BFUE growth. Thus, monocytes produce BPA, and their activation by LPS enhances greatly their ability to generate BPA.

Adult↗

Combination chemotherapy of refractory lymphoma with cis-dichlorodiamineplatinum, vinblastine, and bleomycin.

Therapy of advanced lymphomas after failure of chemotherapy with cytoxan and adriamycin containing combinations remains poor. We have treated 17 patients with refractory lymphomas of various histologies with an intensive regimen of cisplatin, vinblastine and bleomycin. These were three complete clinical responses (6, 10+, 8 months, respectively) and five partial responses (2.5, 3, 4, 7, 18 months, respectively) for a total of 8/17 responders. Four of the eight responders had bone or bone marrow involvement. In addition, three patients had dramatic shrinkage of measureable lesions, but the duration (less than 1 month) was too short to allow classification as a response. Toxicity included severe myelosuppression requiring that patients be hospitalized to the majority of cases, mild to moderate rise in serum creatinine levels in 41% of patients and one case of fatal pulmonary fibrosis. This regimen may be useful in patients with refractory or relapsing lymphoma; alternatively, it may be useful as part of an initial treatment protocol utilizing non-cross-resistant regimens for the management of patients with poor prognosis lymphomas.

Adult↗

Human erythroid burst-forming units. Growth in vitro is dependent on monocytes, but not T lymphocytes.

The roles of monocytes and T lymphocytes in the regulation of human peripheral blood erythroid burst-forming units (BFU-E) were studied in erythropoietin-containing plasma clot cultures of subpopulations of human blood mononuclear cells. BFU-E growth was decreased significantly after depletion of monocytes alone (mean 11% of expected, range 0 to 42% of expected) or depletion of both monocytes and T cells (mean 6.5% of expected, range 0.5 to 12% of expected) from mononuclear cells. T cell depletion did not impair BFU-E growth in vitro. Using 10(5) monocyte- and T lymphocyte-depleted mononuclear cells as target cells (less than 1% monocytes, less than 5% T cells), BFU-E growth was restored to 40% of expected by addition of 10(4) monocytes, and to 96% of expected by 10(5) monocytes alone. Addition of as many as 2 X 10(5) T cells but no monocytes resulted in stimulation to only 34% of expected BFU-E growth. Addition of 2 X 10(4) T cells, which alone did not affect BFU-E growth, could augment significantly the stimulatory effect of 5-20 X 10(3) monocytes on BFU-E growth. Thus, monocytes alone appear to be capable of stimulating BFU-E growth in vitro in the presence of erythropoietin. T cells also may make small quantities of BFU-E stimulators. However, it seems more likely that the most important role of T lymphocytes in BFU-E regulation in vitro is a result of interactions with monocytes and augmentation of monocyte production of stimulators of BFU-E growth.

Cell Differentiation↗

Aplastic anemia: recent advances in pathogenesis and treatment.

Successful bone marrow transplantation and bone marrow culturing techniques have generated a large body of research into the pathogenesis and treatment of aplastic anemia. Most prominent has been the emphasis on autoimmune mechanisms. Several etiologic types and diagnostic criteria are discussed, the evidence supporting immune and other mechanisms of pathogenesis is examined, and results of current therapeutic trials are addressed.

Adrenal Cortex Hormones↗

The role of colony stimulating activity in modulating murine diffusion chamber granulopoiesis.

We studied the effects of high circulating Colony Stimulating Activity (CSA) levels and irradiation induced marrow hypoplasia in CF1 and C57B1/6J host mice upon granulopoiesis in intraperitoneal diffusion chamber (DC) cultures. Serial endotoxin injections resulted in marked elevation of circulating CSA for the first half of an 8 d culture period, and CSA was shown to diffuse into the chamber environment; yet this manipulation alone did not significantly accelerate DC cell growth. Pre-irradiation of the host mice produced no elevation of circulating CSA during the early phase of culture, but resulted in significant stimulation of DC granolopoiesis. Fluctuations in circulating inhibitors of in vitro granulopoiesis did not correlate well with DC cellularity. We conclude that endogenous CSA elevation does not providean effective stimulus per se for granulocyte-monocyte proliferation within DC culture and cannot be solely responsible for mediating the exuberant DC granulopoietic response seen in the pre-irradiated host.

Animals↗

Stimulation of human BFU(E) by products of human monocytes and lymphocytes.

Regulation of normal human peripheral blood BFU(E) by lymphocytes and monocytes was investigated using plasma clot cultures. Monocyte depletion from peripheral blood mononuclear cells (MNC) resulted in 28 to 98% inhibition of BFU(E) growth in 16 of 17 experiments, but T lymphocyte depletion caused no decrease in BFU(E). When both T cells and monocytes were removed there was an 80% decrease in BFU(E) growth. Addition of as few as 10(4) monocytes alone increased BFU(E) to 88% of expected levels, but addition of 5 x 10(4) T lymphocytes resulted in an increase to only 57% of anticipated BFU(E) numbers. Conditioned media (CM) from 5 x 10(5) to 10(6) unstimulated T lymphocytes per ml stimulated BFU(E) growth from cultures of non-adherent cells, but not from cultures of T cell depleted MNC. Monocyte CM produced peak (2.2-fold) stimulation with only 10(5) monocytes/ml. CM from 5 x 10(5) to 10(6) monocytes/ml had no detectable erythroid burst promoting activity (BPA). Thus, unstimulated monocytes produce BPA, and at high cell concentrations, also produce a presumed inhibitor of BPA production or biologic activity. Although T cells may play some role in control of BFU(E), monocytes appear to be critical for optimal BFU(E) growth in vitro.

Cells, Cultured↗

Aplastic anemia: lack of inhibitory effect of bone marrow lymphocytes on in vitro granulopoiesis.

Prompted by previous reports that in certain patients with aplastic anemia, cell-mediated autoimmune suppression of myeloid stem cell proliferation may be demonstrable in vitro, we studied the effects of bone marrow lymphocytes from 18 patients with myeloid aplasia on the proliferation of committed granulocytic-monocytic progenitor cells (CFU-C). When assayed in soft agar cultures, marrow suspensions from 10 patients with aplastic anemia contained significantly fewer viable CFU-C than similar cell preparations from control subjects. To deplete marrow cell suspensions of lymphocytes, we employed rabbit anti-human thymocyte serum (ATS), which after multiple adsorptions exhibited marked cytotoxicity for human B and T lymphocytes but had negligible effect on normal CFU-C proliferation. Preincubation of marrow samples from 12 patients with ATS and complement resulted in no inhibition or enhancement of CFU-C growth. In further experiments, marrow cells from 8 patients were incubated with marrow from control subjects prior to CFU-C culture. No suppression of donor CFU-C proliferation was observed in any of these studies, and in 4 cocultures, mixture of the 2 marrow suspensions resulted in stimulation of CFU-C growth. Using these assays, we detected no evidence of cell-mediated inhibition of CFU-C proliferation in any of the 18 patients that we evaluated. Our data support the conclusion that in the majority of patients with aplastic anemia, an absolute deficiency of hemopoietic stem cells is present within the marrow that does not appear to be effected or sustained by suppressor lymphocytes. Whether the reduction of viable stem cells is the cause or the consequence of the process that leads to marrow failure remains unknown.

Anemia, Aplastic↗

Contamination of erythropoietin by endotoxin: in vivo and in vitro effects on murine erythropoiesis.

Endotoxin was detected in all erythropoietin preparations tested and was removed from four lots, without loss of erythropoietic activity, by adsorption with limulus amebocyte lysate. Comparison of adsorbed (endotoxin-depleted) and nonadsorbed (endotoxin-containing) erythropoietin preparations demonstrated significant inhibition of CFU-e and BFU-e in vitro by nonadsorbed erythropoietin at concentrations higher than 0.25 U/ml and 2.0 U/ml, respectively. CFU-e and BFU-e were inhibited significantly by readdition in vitro of 10(-5)-10(-3) mug of endotoxin per unit of limulus-adsorbed erythropoietin. Administration of saline or 6 U of nonadsorbed or adsorbed erythropoietin twice a day for 4 days of CF1 mice resulted in reticulocyte counts of 2.1%, 9.9%, and 15.9%, respectively. Nonadsorbed erythropoietin resulted in a 29% decrease in erythropoiesis, a 42% decrease in CFU-e, and a 16% increase in granulopoiesis in the marrow, whereas adsorbed erythropoietin caused a 28% increase in erythropoiesis, no significant change in CFU-e and a 19% decrease in granulopoiesis in the marrow. Both preparations resulted in marked increases in splenic erythropoiesis and granulopoiesis. The effects of adsorbed erythropoietin are similar to those produced following stimulation of hematopoiesis by endogenous erythropoietin. Hemopoietic changes induced by nonadsorbed erythropoietin in vivo and in vitro are affected substantially by contamination of the erythropoietin preparations with endotoxin.

Adsorption↗

Effects of actinomycin D in vivo on murine erythroid stem cells.

Low-dose actinomycin D (Acto) selectively suppresses murine erythropoiesis without decreasing erythropoietin (Ep) production. We used the plasma clot system to determine the stage of erythroid differentiation at which this inhibition occurs. Late erythroid precursors, CFU-E, and less differentiated committed erythroid stem cells, BFU-E, were assayed in CF1 mice given Acto 75-82 microgram/kg/day or saline subcutaneously for 5 days. We also assayed pluripotent (CFU-S) and committed granulocyte-monocyte (CFU-C) stem cells. Reticulocytes and marrow and spleen nucleated erythroid precursors were decreased by 99% in the Acto-treated mice; tibial marrow CFU-E were decreased by 97% and splenic CFU-E by 99%. Tibial BFU-E were not decreased by Acto, although there was a 66% diminution in splenic BFU-E. Acto increased tibial CFU-S, but splenic CFU-S and tibial and splenic CFU-C were unchanged. Thus Acto inhibits erythropoiesis by suppressing the ability of immediate committed erythroid precursors of CFU-E or CFU-E themselves to differentiate further in response to Ep. Acto does not affect survival or proliferation of the less differentiated cells--CFU-C, CFU-S, and marrow BFU-E. The suppression of splenic BFU-E in Acto-treated mice may indicate that marrow and splenic BFU-E are basically different stem cells. Alternatively, Acto treatment may impair migration of BFU-E from marrow to spleen.

Animals↗